We provide you with 20 years of free, institutional-grade data for PFE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PFE. Explore the full financial landscape of PFE stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| DAMICO JENNIFER B. | Grant, award...etc | 5,583 | 2025-03-06 | ||
| DAMICO JENNIFER B. | Sale | -3,249 | $26.1 | $84,799 | 2025-03-06 |
| McDermott Michael | Sale | -46,455 | $26.1 | $1,212,476 | 2025-03-03 |
| McDermott Michael | Derivatives Exercise | 48,419 | 2025-03-03 | ||
| LANKLER DOUGLAS M | Sale | -150,550 | $26.1 | $3,929,355 | 2025-03-03 |
| LANKLER DOUGLAS M | Derivatives Exercise | 156,914 | 2025-03-03 | ||
| Fonseca Lidia | Sale | -69,705 | $26.1 | $1,819,301 | 2025-03-03 |
| Fonseca Lidia | Derivatives Exercise | 72,629 | 2025-03-03 | ||
| BOURLA ALBERT | Sale | -564,155 | $26.1 | $14,724,446 | 2025-03-03 |
| BOURLA ALBERT | Derivatives Exercise | 582,823 | 2025-03-03 | ||
| DAMICO JENNIFER B. | Sale | -21,924 | $26.1 | $572,216 | 2025-03-03 |
| DAMICO JENNIFER B. | Derivatives Exercise | 22,416 | 2025-03-03 | ||
| SUSMAN SALLY | Sale | -81,957 | $26.1 | $2,139,078 | 2025-03-03 |
| SUSMAN SALLY | Derivatives Exercise | 85,182 | 2025-03-03 | ||
| BOSHOFF CHRISTOFFEL | Sale | -9,312 | $26.1 | $243,043 | 2025-03-03 |
| BOSHOFF CHRISTOFFEL | Grant, award...etc | 17,450 | 2025-03-03 | ||
| SAHNI PAYAL | Sale | -18,314 | $26.1 | $477,995 | 2025-03-03 |
| SAHNI PAYAL | Derivatives Exercise | 19,054 | 2025-03-03 | ||
| BOSHOFF CHRISTOFFEL | Sale | -4,872 | $26.42 | $128,718 | 2025-02-28 |
| BOSHOFF CHRISTOFFEL | Grant, award...etc | 9,687 | 2025-02-28 | ||
| McDermott Michael | Sale | -3,220 | $26.42 | $85,072 | 2025-02-28 |
| SUSMAN SALLY | Sale | -59,500 | $26.3 | $1,564,850 | 2025-02-25 |
| SUSMAN SALLY | Derivatives Exercise | 63,573 | 2025-02-25 | ||
| SAHNI PAYAL | Sale | -11,911 | $26.3 | $313,259 | 2025-02-25 |
| SAHNI PAYAL | Derivatives Exercise | 12,714 | 2025-02-25 | ||
| BOSHOFF CHRISTOFFEL | Sale | -8,800 | $26.3 | $231,440 | 2025-02-25 |
| BOSHOFF CHRISTOFFEL | Derivatives Exercise | 8,741 | 2025-02-25 | ||
| DAMICO JENNIFER B. | Sale | -8,578 | $26.3 | $225,601 | 2025-02-25 |
| DAMICO JENNIFER B. | Derivatives Exercise | 8,741 | 2025-02-25 | ||
| McDermott Michael | Sale | -10,422 | $26.3 | $274,099 | 2025-02-25 |
| McDermott Michael | Derivatives Exercise | 11,125 | 2025-02-25 | ||
| BOURLA ALBERT | Sale | -221,515 | $26.3 | $5,825,845 | 2025-02-25 |
| BOURLA ALBERT | Derivatives Exercise | 238,399 | 2025-02-25 | ||
| LANKLER DOUGLAS M | Sale | -79,899 | $26.3 | $2,101,344 | 2025-02-25 |
| LANKLER DOUGLAS M | Derivatives Exercise | 85,824 | 2025-02-25 | ||
| BLAYLOCK RONALD E | Open Market Purchase | 19,457 | $25.65 | 2025-02-14 | |
| BOSHOFF CHRISTOFFEL | Sale | -12,038 | $26.52 | $319,248 | 2025-02-04 |
| Gottlieb Scott | Open Market Purchase | 1,000 | $28.24 | 2024-10-31 | |
| MALIK AAMIR | Sale | -20,195 | $29.01 | $585,857 | 2024-09-03 |
| DAMICO JENNIFER B. | Sale | -5,154 | $28.66 | $147,714 | 2024-08-14 |
The information provided in this report about PFE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Pfizer Inc(NYSE:PFE) 
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, s...
Website: http://www.pfizer.com
Founded: 1849
Full Time Employees: 83,000 (Dec 2022)
CEO: Albert Bourla
Sector: Healthcare
Industry: Drug Manufacturers-General
